Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Overview of attention for article published in Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease, September 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 211,867 followers.

Using alirocumab (PCSK9i) at 150 mg once monthly https://t.co/mQHEPaQlsl @nationallipid

RT @JAHA_AHA: Stroes et al: Alirocumab 150 mg in patients with hypercholesterolemia not on statin therapy https://t.co/1IHoUSaog8 https://t…

Stroes et al: Alirocumab 150 mg in patients with hypercholesterolemia not on statin therapy https://t.co/1IHoUSaog8 https://t.co/UKwphDusd0

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.